Spotlights follow Alycia Baumgardner wherever she goes these days. She returns to the ring tomorrow in a major moment. This fight marks her first main event under Most Valuable Promotions. It also headlines the company’s first prime time card on ESPN since their new partnership.
The event carries weight for more than one reason. Most Valuable Promotions has pushed a clear message about equality in women’s boxing. The company, led by Jake Paul and Nakisa Bidarian, wants to give female fighters equal footing. Alycia Baumgardner stands front and center in that mission.
It unfolds at The Theater at Madison Square Garden. Baumgardner faces Bo Mi Re Shin in the main event. Everything about the event signals growth, investment, and attention.
However, not every return earns that kind of stage.
Across state lines, Christina Linardatou also steps back into the ring this weekend. Her comeback happens quietly. Few headlines mention it. Fewer fans even know.
She fights under Swift Promotions at the Showboat Hotel in Atlantic City. No major broadcast surrounds the event. No sweeping narrative builds anticipation. The contrast feels sharp.
Yet both fighters remain tied together by more than shared history.
They represent a troubling chapter in boxing. That chapter centers on failed drug testing systems. It also exposes how uneven accountability can be. In this case, visibility and backing seem to matter more than clarity or justice.
To understand that divide, go back to July 2023.
At the time, Baumgardner fought under Matchroom Boxing, led by Eddie Hearn. She entered a rematch against Linardatou, the only fighter to beat her. The bout took place at the Masonic Temple in Detroit.
Baumgardner won by unanimous decision. She avenged her lone defeat. On paper, the story ended there.
Instead, everything unraveled soon after.
A urine sample collected three days before the fight tested positive. The results showed metabolites of mesterolone and methenolone acetate. Both substances fall under anabolic steroids. They can enhance strength and recovery.
As expected, Baumgardner denied wrongdoing. She pointed to independent hair testing as proof. According to her statement, the test covered June through August 2023. It found no trace of banned substances.
Even so, the Michigan Unarmed Combat Commission acted quickly. Officials issued an indefinite suspension. That decision suggested serious concern at the time.
However, the suspension did not last.
By March, the commission lifted it. The move came just months after the positive test. When pressed for details, the commission stayed silent. Officials did not release findings. They did not explain conclusions.
That silence extended to Linardatou.
She, along with promoter Lou DiBella, sought answers. They received none. Requests for transparency went nowhere.
Sanctioning bodies also failed to act in any meaningful way.
The World Boxing Council acknowledged the valid test. Still, it said no conclusive proof showed intentional doping. The World Boxing Organization issued a show cause order. That action never led to anything further. Meanwhile, the International Boxing Federation and World Boxing Association stayed quiet.
As a result, the sport moved on.
Many accepted the outcome without much resistance. The narrative shifted back to performance and promotion. Questions faded from the spotlight.
Linardatou never accepted that version of events.
She believes the rematch felt different. In her view, Baumgardner showed unusual strength. She has said as much in clear terms. Her stance has not changed.
Moreover, she continues to push for fairness. She wants the loss removed. She also wants a third fight under stricter testing.
That opportunity has not come.
In a more consistent system, a trilogy might have made sense. Stronger testing could have settled doubts. Instead, the issue remains unresolved.
This outcome reflects a deeper problem in boxing.
The sport has long struggled with regulation. Different commissions operate under different standards. Enforcement often lacks consistency. High profile fighters sometimes benefit from that reality.
Consequently, trust erodes.
Fans notice when rules seem flexible. Fighters notice when accountability varies. Over time, that pattern damages credibility.
Now, the contrast between these two fighters feels even sharper.
Baumgardner stands at the center of a major promotional push. She headlines a prime time card. She represents progress for women’s boxing. Her career continues to rise.
At the same time, Linardatou fights in near silence. Her return lacks recognition. Her questions remain unanswered.
Both realities exist side by side.
As Alycia Baumgardner prepares for her next challenge, the past no longer dominates headlines. The scandal has faded from public focus. Attention shifts to new opponents and new opportunities.
Meanwhile, Linardatou still searches for closure. Her pursuit of justice has ended unresolved. In boxing, it often does.
Her career continues without the same spotlight or support. She fights on, but without the same stage.
